Manufacturer record
Reltsen Health Care: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Reltsen Health Care (Puducherry) were declared Not of Standard Quality between December 2022 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: R25183701K, Ramipril Tablets IP 5mg (exp Oct 2027). Drugs Testing Laboratory, Madurai-19 (state lab) found it not of standard quality: Ramipril (64.20%). Listed in the July 2026 alert.
Records by type
2 records linked to Reltsen Health Care in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Ramipril Tablets IP 5mg | Batch R25183701KMfg Nov 2025 · Exp Oct 2027 | Ramipril (64.20%)Other | Drugs Testing Laboratory, Madurai-19State lab | Jul 2026 |
| MYLOMAX (Methylcobalamin, Alpha Lipoic Acid, Folic Acid, Pyridoxine Hydrochloride & Vitamin D3 Tablets) | Batch R2295307GMfg Jul 2022 · Exp Dec 2023 | Assay of Alpha Lipoic AcidAssay | CDL KolkataCDSCO lab | Dec 2022 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.